Novoseven, Novoseven RT Market Report 2026

Novoseven, Novoseven RT Market Overview

• The Novoseven, Novoseven RT market growth in the historic period has been driven by rising diagnosis of rare bleeding disorders, increased use of bypassing agents in hemophilia care • Market expansion is supported by increasing focus on personalized bleeding disorder management, rising demand for rapid-acting clotting agents • Growth Driver: Rising Hemophilia Cases Driving Growth Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Novoseven, Novoseven RT Market?

Novoseven and novoseven RT are recombinant activated factor VII (rFVIIa) medications designed to aid blood clotting in individuals with specific bleeding disorders, such as hemophilia A or B with inhibitors, congenital factor VII deficiency, and Glanzmann’s thrombasthenia. They are primarily used to control bleeding episodes and during surgical or invasive procedures in these patients. The main indications of the novoseven, novoseven RT market are hemophilia A, hemophilia B, and other rare disorders. Hemophilia A is a genetic disorder caused by a deficiency or dysfunction of clotting factor VIII, leading to prolonged bleeding episodes. This condition requires continuous management to prevent spontaneous or excessive bleeding, which can be life-threatening if not treated properly. The various distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies and are used by several end users such as adult patients, pediatric patients, and geriatric patients.

What Is The Novoseven, Novoseven RT Market Growth Forecast?

The growth in the forecast period can be attributed to increasing focus on personalized bleeding disorder management, rising demand for rapid-acting clotting agents, expansion of global access programs, advancements in recombinant drug manufacturing, growing adoption in emergency bleeding scenarios. Major trends in the forecast period include increasing use of recombinant coagulation therapies, growing adoption in surgical bleeding management, expansion of indications for rare bleeding disorders, enhanced focus on rapid hemostasis solutions, improved cold-chain distribution practices.

What Are The Drivers Of The Novoseven, Novoseven RT Market?

The growing prevalence of hemophilia is expected to propel the growth of the novoseven, novoseven RT market going forward. Hemophilia is a rare genetic bleeding disorder caused by a deficiency or absence of specific clotting factors in the blood, which impairs the body's ability to form proper blood clots, leading to prolonged or spontaneous bleeding, especially after injuries or surgeries. The prevalence of hemophilia is growing due to improved diagnosis, better management increasing life expectancy, and population growth. Novoseven, novoseven RT are useful for hemophilia treatment, as they provide a recombinant activated factor VII therapy that effectively helps control and prevent bleeding episodes in patients, particularly those with inhibitors to standard clotting factor therapies, ensuring better management of this genetic bleeding disorder. For instance, in April 2025, according to the Hemophilia News Today, a US-based privately owned digital media organization, reported that the global prevalence of hemophilia, that is, the number of people who have it, is estimated to be about 836,000 people, according to worldwide statistics. Therefore, the growing prevalence of hemophilia is driving growth in the novoseven, novoseven RT industry. The increasing healthcare expenditure is expected to propel the growth of the novoseven, novoseven RT market going forward. Healthcare expenditure refers to the total financial resources spent by individuals, governments, or organizations on medical goods, services, public health initiatives, and related administrative or research activities to maintain and improve health. The increase in healthcare expenditure is due to aging populations, the rising prevalence of chronic diseases, and the growing need for better healthcare infrastructure, leading to higher global healthcare expenditures. Novoseven, novoseven RT contribute to helping healthcare expenditure by providing effective and targeted treatments for severe bleeding conditions, such as hemophilia and postpartum hemorrhage, potentially reducing the need for costly emergency interventions, prolonged hospital stays, and additional medical procedures, improving cost-efficiency in managing critical health conditions. For instance, in June 2024, according to Health Affairs, a US-based nonprofit organization, U.S. healthcare spending is projected to grow from 17.3% of GDP in 2022 to 19.7% by 2032, with a 7.5% increase in national health expenditures estimated for 2023. Therefore, increasing healthcare expenditure drives growth in the novoseven, novoseven RT industry. The rising number of complex surgical procedures is expected to propel the growth of the NovoSeven and NovoSeven RT market going forward. Complex surgical procedures are operations that involve high risk, multiple steps, or specialized techniques to treat severe or complicated medical conditions. The increase in complex surgical procedures is largely driven by the growing prevalence of chronic diseases and advanced medical conditions that require intricate interventions. NovoSeven and NovoSeven RT support complex surgical procedures by effectively controlling bleeding in patients with hemophilia or acquired coagulation deficiencies. For instance, in November 2024, according to the Private Healthcare Information Network (PHIN), a UK-based nonprofit organization, in Q1 2024, 22,700 robot-assisted procedures were performed, marking a 45% rise from Q1 2023 and a 12% increase from Q4 2023. Therefore, the rising number of complex surgical procedures is driving the growth of the NovoSeven and NovoSeven RT market.

Key Players In The Global Novoseven, Novoseven RT Market

Major companies operating in the novoseven, novoseven rt market are Novo Nordisk A/S

What Defines the Novoseven, Novoseven RT Market?

The novoseven, novoseven RT market consists of sales of recombinant factor viii, activated prothrombin complex concentrates, and cryoprecipitate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Novoseven, Novoseven RT Market Report 2026?

The novoseven, novoseven rt market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the novoseven, novoseven rt industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.